Incyte is getting sold like a one-drug biotech just as the business is starting to look broader, cleaner, and cheaper than that label implies. The key disconnect is simple: total revenue grew 21.2% year over year while the stock still carries only a 14.33x trailing P/E and a 3.84x sales multiple. That is not how the market usually prices a company with 26.7% net margins, a fresh FDA approval in hand, and another meaningful regulatory date on the calendar. We think the market narrative is behind the fundamentals.
The first reason the one-drug story falls apart is that the growth is no longer coming from one place. In Q1 2026, Incyte posted $1.27 billion in revenue, up 21% year over year, while Jakafi itself grew 7% to $758 million. That gap matters. It shows the rest of the portfolio is finally doing real work, with management calling out growth across Opzelura, Niktimvo, Monjuvi, and Zynyz. A company whose top line is growing three times faster than its flagship product is not standing still.
The second reason is that this is no longer just a pipeline promise. Jakafi XR won FDA approval on May 1, turning a regulatory overhang into a commercial launch. Management has already embedded that launch into 2026 guidance, which calls for total net product revenue of $4.77 billion to $4.94 billion, including $3.22 billion to $3.27 billion from Jakafi. That still leaves Jakafi as the anchor, but it also reframes the franchise as broader than a single aging asset. Add the September 26 priority-review date for povorcitinib in hidradenitis suppurativa, and the next leg of the story is close enough for the market to underwrite.
The valuation makes that setup harder to ignore. INCY carries a TickerSpark Score of 98, with sub-scores of 93 for Valuation, 100 for Profitability, 95 for Growth, and 100 for both Financial Health and Momentum. Those numbers line up with the operating profile: 92.5% gross margin, 27.1% operating margin, and 29.3% ROE. Against peers, the stock also looks undemanding. United Therapeutics trades at 20.31x earnings with 10.6% revenue growth, while Royalty Pharma sits at 28.67x earnings with 5.1% growth. Incyte is growing faster than both and trading cheaper than both.
The pushback is real, and it starts with Jakafi still dominating the base. At $758 million in Q1 and with full-year guidance implying roughly two-thirds of product revenue still comes from Jakafi, the market is not wrong to worry about concentration and the eventual patent cliff. That concern is exactly why the stock has been treated cautiously despite strong execution.
The problem with leaning too hard on that bear case is that it ignores the transition already underway. If Incyte were merely defending a mature franchise, it would not be putting up 21.2% revenue growth, 26.7% net margins, and a 4018.8% jump in EPS growth while stacking fresh catalysts. Even the tape is acting better than the narrative suggests: the shares are above the 20-day, 50-day, and 200-day moving averages, with market data showing accumulation and improving sentiment. This still has Jakafi risk, but the market is pricing that risk as if the rest of the business barely exists.
That leaves INCY looking like a stock we would lean into on weakness rather than one to fade after every biotech wobble. The setup is not about chasing a moonshot; it is about recognizing that a profitable large-cap biotech with a 14.33x P/E, 21.2% revenue growth, and a live September FDA catalyst should not trade like a story with no second act. As long as the company keeps showing that non-Jakafi assets can lift the mix, the current narrative stays too bearish.
What we would watch from here is straightforward: confirmation that Jakafi XR is contributing to the franchise, and any regulatory progress into the September povorcitinib decision. The cleanest reason to change our mind would be evidence that the broader portfolio is stalling and growth snaps back to pure Jakafi dependence. Until that happens, the market's one-drug framing looks increasingly out of date.
